Aclaris Therapeutics has initiated a Phase 1b proof-of-concept trial evaluating ATI-052, a bispecific antibody designed to simultaneously target TSLP and IL-4Rα pathways implicated in asthma pathogenesis. The candidate therapy represents a novel approach to addressing multiple inflammatory mechanisms relevant to the disease, building on the company's recent advancement of the same compound in atopic dermatitis.
The dual-indication development strategy reflects growing evidence that coordinated inhibition of TSLP and IL-4Rα signaling may offer enhanced therapeutic benefit across multiple type 2 inflammatory conditions. Aclaris expects to report top-line data from both the asthma and atopic dermatitis Phase 1b trials during the second half of 2026, with plans to advance the program into Phase 2b studies thereafter pending positive efficacy and safety findings.
The company's concurrent pursuit of asthma and atopic dermatitis indications leverages the shared immunologic underpinnings of these conditions while potentially expanding the commercial opportunity for ATI-052 if clinical outcomes support advancement in both disease areas.